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a b s t r a c t
Hemolysis related to occluder, prosthetic valve, and prosthetic ring used for mitral valve
annuloplasty are not very unusual. However, hemolysis related to transcathetor closure of
post-myocardial infarction ventricular septal defect (PMIVSD) is infrequent. A close follow-
up for spontaneous resolution with or without blood transfusion has been reported in a few
cases. Occasionally, surgical retrieval is unavoidable or lifelong blood transfusion is required
if surgery cannot be done because of higher risk. In this illustration, we have showed a close
follow-up of a case of hemolysis induced by atrial septal occluder used for VSD closure after
myocardial infarction. Despite successful device closure of PMIVSDwhich is difﬁcult, a close
watch is needed for complications like residual leak, device embolization, and hemolysis.
# 2016 Cardiological Society of India. Published by Elsevier B.V. This is an open access
article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. IntroductionHemolysis induced by prosthetic material used to occlude,
replace, or repair the structural cardiac defects is not very
infrequent either in intervention cardiology or cardiovascular
surgery. The encounter has a rising trend because of
signiﬁcant rise in device-based treatment. The unavoidable
residual leaks, which are featured by high velocity, vortices,
and rapid deceleration, impose signiﬁcant shear on red blood
cells leading to hemolysis. Transcathetor closure (TCC) of post-
myocardial infarction ventricular septal defect (PMIVSD) is
difﬁcult and not practiced frequently. Also, the experience of
treating hemolysis induced by occluder used in this condition
is rare (0.02–0.035%).1,2 A close follow-up for spontaneous* Corresponding author.
E-mail address: cardioramachandra@gmail.com (R. Barik).
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0019-4832/# 2016 Cardiological Society of India. Published by Elsevier
(http://creativecommons.org/licenses/by-nc-nd/4.0/).resolution with or without blood transfusion have been
reported in a few cases.3,4 Occasionally, surgical retrieval
and repair are unavoidable.5
2. Illustration of the caseA49-year-oldmale presentedwith history of ventricular septal
rupture after thrombolysis for anterior wall myocardial
infarction. He was in Killip's class III for last 6 weeks post-
myocardial infarction. At presentation, he had features of
signiﬁcant left heart failure (orthopnoea and crepitation in
both the lung ﬁelds) and right heart failure (pedal edema,
raised JVP, and ascites). Precordial examination revealed grade
III parasternal lift, loud P2, and III/VI pansystolic murmur.B.V. This is an open access article under the CC BY-NC-ND license
[(Fig._1)TD$FIG]
Fig. 1 – (A) 2D echo shows a large ventricular defect of size 2.1 cm in middle part of interventricular septum with mid-distal
septal aneurysm; (B) Coronary angiogram in right anterior oblique (RAO) view shows critical type B stenosis in the middle
part of LAD which was stented and the scene angiogram shows atrial septal occluder (Cardi-O-Fix, 28 mm) across the
ventricular septal defect immediately following the TCC; (C) Echo shows a stable and better aligned device plugging the VSD
at the end of one-month follow-up; (D) Serial changes in color of urine from 2nd day device closure till the day of discharge.
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The coronary angiogram which was done outside, revealed
critical stenosis of mid part of left anterior descending
coronary artery (LAD). The patient was nondiabetic and
nonsmoker. 2D echo showed hypokinetic anterior wall, septal
aneurysm of distal IVS and apex, ventricular septal defect of
size 2.1 cm, signiﬁcant left to right shunt, gradient of 35 mmHg
across VSD, and near systemic right ventricular pressure with
signiﬁcant right ventricular dysfunction [Fig. 1A, Video 1 and
Video 2]. After medical stabilization for 48 h and proper
consent, we planned for TCC of VSD and angioplasty of LAD.
After hemodynamic study on oxygen, we successfully plugged
the VSD using an atrial septal occluder of size of 28 mm (Cardi-
O-Fix) via right internal jugular venous approach. A critical
lesion in the LAD was directly stented using 2.5 mm  12 mm
Taxus stent [Fig. 1B and Video 3]. This was followed by post-
procedure hemodynamic study to evaluate the impact of
device closure. Intra-aortic balloon pump was not used in this
case because of stable hemodynamic. Therewere tiny residual
leaks around the device with insigniﬁcant left to right shunt.
But unfortunately, this patient developed intense hemolysis
on second day of the procedure marked by signiﬁcant drop in
hemoglobin, hemoglobinuria (Coca-Cola colored urine), sig-
niﬁcant elevation of lactate dehydrogenase (LDH), systocytes
in peripheral smear, mild elevated reticulocyte count, high
level of unconjugated bilirubin, positive urobilinogen in urine,
and jaundice. Echo on day three showed mild residual shunt
across the device due to poor apical rims which is common inlarge ventricular septal defect after myocardial infarction. The
device was almost parallel to the muscular septum and not
well seated on the RV side [Fig. 1C, Video 4]. One unit of fresh
packed red blood cell (PRBC) was transfusedwhen hemoglobin
dropped from 13 g% to 7 g%. Urine color changed gradually
from Coca-Cola to normal over a period 11 days of his ICCU
stay [Fig. 1D]. An abridged summary of his periprocedural
clinical condition, hemodynamic study (non-invasive and
invasive), and experience of device closure including one-
month follow-up have been included in Table 1. He was
successfully discharged without further episode of hemolysis.
At the end of ﬁrst-month follow-up, device positionwas stable,
there was further signiﬁcant decrease in residual leaks [Video
5] and no more evidence of hemolysis.
3. DiscussionTCC of VSD after MI is an effective alternative to surgical
closure especially in subacute or chronic condition.1 The
closure by surgery or device is not immune to residual leaks.6,7
Though the persistent residual leak is frequent with TCC, it is
rarely associated with hemolysis by several mechanisms as
have been mentioned before. We have not come across
hemolysis related to TCC of PMIVSD in experience of
consecutive 7 cases from 2012 to 2015.8,9 The unavoidable
residual leaks, which are featured by high velocity jets,
vortices, and rapid deceleration, impose signiﬁcant shear on
Table 1 – Periprocedural observation of TCC of PMIVSD using atrial septal occluder.
Items Days in hospital
1–4th 5th 6th–15th 16th
Clinical Killip's III,
Anasarca
PSM: III/VI
TCC Dramatic improvement in general condition, HR and BP was
stable. Jaundice appeared but improved on follow up toward
discharge. PSM – III/VI
Discharged
ECG Baseline is Q in V1–V4 but developed RBBB after device closure
X-ray chest Cardiomegaly; pulmonary edema and right sided pleural effusion which improved dramatically after TCC
ECHO Baseline: Aneurysm of mid part of IVS, size of VSD is 2.1 cm, RVSP of 90 mmHg, LVEF – 35–40%, TAPSE of 0.8 cm, LV-RV
gradient of 35 mmHg and thin rim of pericardial effusion
Post-procedure: Tiny residual shunts through or around ASO, RVSP – 30 mmHg
1-Month follow-up echo: Stable device position, tiny residual shunt and normal PA pressure
Invasive
hemodynamic
(on O2)
Baseline: HR – 85 min–1, Saturations (%): SVC – 44, IVC – 59, RA – 55, RV – 97, PA – 96, FA – 99; Pressure (mmHg): RA – 16,
RVs – 90/10, PA – 90/26/52, PCWP – 20, LV – 128/16, FA – 120/80/94, signiﬁcant left to right shunt
Post-ASO closure: Saturation (%): RA – 54, RV – 58, PA – 59; FA – 99.2; Pressure (mmHg): RA – 12, RV – 58/10, PA – 55/26/38,
FA – 150/80, PCWP – 16, QP/QS: reduced signiﬁcantly
Urine Pre-procedure: Amber color and normal
Post ASO closure: Urine color changed deep Coca-Cola color on day-2, gradually returned to amber color on 8th day post
procedure with one unit blood transfusion. There was no hematuria. Test for Urobilinogen was positive
Liver enzymes Baseline: Mildly elevated (SGOT and SGPT)
Post closure: Mild changes
Hemoglobin (g/dl) Baseline: 13
Post-procedure: Lowest 7.2 on the 8th day of TCC, improved to 9.2 after 1 unit of blood transfusion and remained stable
Bilirubin: total/
conjugated
(mg/dl)
Baseline: 1.9/0.9
Post-procedure: Peak – 7.2/0.9, peak conjugated bilirubin was 2.2 and at discharge it was 3.2/0.8
Blood urea/serum
Cr (mg/dl)
40/1.2 at baseline remained near normal during hospital
Other tests Platelet count: 6  105 mm–3 (periprocedural mild changes)
LDH: 2361 IU/L on 2nd day of procedure which improved gradually
Reticulocyte count – No signiﬁcant changes
Platelet aggregation test by light aggregometry: 10%
Peripheral smear for systocyte: 1–5/HPF
Test for malaria parasite: Negative
Coomb's test: Negative
Viral markers: Negative
Treatment Improving CHF TCC and PCI Dual antiplatelet
(Prasugrel and aspirin)
was changed to only
aspirin and again
changed to dual antiplatelet
at time of discharge
1 unit of PRBC Watched Discharged
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multiple defects, ongoing remodeling, serpiginous pathway,
aneurysm, improper size of the device, and incorrect align-
ment of device during implantation are the several reasons for
devicemalposition leading to tiny high velocity residual leaks.
In our case, we feel a little oversizing of device and associated
aneurysm of apical interventricular septum were the reasons
for underexpansion of the neck of the device and its discs
leading to residual shunt, which may be the reason for
hemolysis. The proper evaluation of location, size, shape,
number of defects, and aneurysm should be done prior to the
TCC, which may reduce the incidence of device-related
hemolysis. There are several ways to reduce residual leaks,
which have been addressed as follows. The approved device
for TCC of PMIVSD is dedicated Amplatzer PMIVSD occluder
(AGA Medical Corp., Golden Valley, Minnesota, USA). The
maximum size of VSD which can be closed by this device is
25 mm.12 If the size of VSD is larger than 24 mm, ASD occluder
can be used. A previous report suggests a defect size of 15 mm
should be treated with percutaneous therapy, either as atemporary strategy and to stabilize the patient until a
deﬁnitive surgical repair can be accomplished because larger
size occluder leads to higher rate residual leak because of
malposition.7 Routinely, the size of device chosen for TCC of
PMIVSD is 50%higher than defect (waist of device to defect size
ratio is 150%) in acute condition because of unreliable borders,
shape, and ongoing remodeling. In chronic condition, the size
of waist of the chosen device should be 4 mm higher than
defect size, which would adjust any further remodeling. In our
case, though the age of defect was more than 6 weeks, the
borders of the defect could not be reliably assessed by 2D echo.
Therefore, we have chosen a device of size 28 mmwith defect
to device ratio of 21:28 (130%). We have chosen ASD occluder
in our case for two reasons: (1) a defect size of 21 mmand (2)we
thought a larger disc on LV side would provide a stable device
position. Because of the complex shape and nature of the
defects, 2D and 3D echo do not seem to fully describe the
anatomy as the proper window is limited in such critically ill
patients as in our case. Therefore, computed tomography or
magnetic resonance imaging should be used to better
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ASD and PDA occluder and coils can be used by experienced
operators.12–14 The role of balloon sizing is controversial in this
condition unlike congenital ASD or VSD. If the defect is too
much complex, it may need more than one device15 and
procedure can be staged. Till now, the shape of the chosen
device is limited to the choice of the individual operator
depending upon the 3D shape of defect.
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